California Seeks Paramount Divestitures in Warner Bros. Merger 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trump Buys SpaceX Shares After Record IPO 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
